Harbor Capital Advisors Inc. Has $3.34 Million Stock Position in LivaNova PLC (NASDAQ:LIVN)

Harbor Capital Advisors Inc. increased its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 101.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,913 shares of the company's stock after acquiring an additional 42,728 shares during the period. Harbor Capital Advisors Inc. owned about 0.16% of LivaNova worth $3,335,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its stake in shares of LivaNova by 29.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company's stock worth $292,000 after purchasing an additional 1,424 shares in the last quarter. Rhumbline Advisers increased its holdings in LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock worth $8,240,000 after buying an additional 899 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in LivaNova during the fourth quarter worth $2,772,000. Envestnet Asset Management Inc. lifted its stake in LivaNova by 15.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 43,932 shares of the company's stock valued at $2,034,000 after acquiring an additional 5,850 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC lifted its stake in LivaNova by 147.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 98,940 shares of the company's stock valued at $4,582,000 after acquiring an additional 58,911 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Stock Performance

NASDAQ LIVN traded down $0.87 on Friday, reaching $45.76. The stock had a trading volume of 417,134 shares, compared to its average volume of 645,374. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $57.35. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.50 billion, a P/E ratio of 108.95 and a beta of 0.90. The firm has a fifty day moving average of $40.58 and a two-hundred day moving average of $43.92.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LIVN. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a report on Tuesday, May 20th. The Goldman Sachs Group dropped their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Wall Street Zen downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird boosted their target price on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Barclays cut their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, LivaNova currently has a consensus rating of "Buy" and an average target price of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.